Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 19/20 | 0.62 |
| ▸ | MTOR | P42345 | 10/20 | 0.62 |
| ▸ | AKT1 | P31749 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15649465 | 0.86 | PIK3CD (0.52) | PIK3CDPIK3CAMTOR | |
| SCHEMBL2924984 | 0.86 | PIK3CD (0.62) | PIK3CDPIK3CAMTOR | |
| SCHEMBL731743 | 0.86 | PIK3CD (0.70) | PIK3CDPIK3CAMTOR | |
| SCHEMBL115582 | 0.83 | PIK3CD (0.70) | PIK3CDPIK3CAMTORAKT1 | |
| SCHEMBL1544054 | 0.83 | LMNA (0.54) | PIK3CDPIK3CAMTORAKT1 | |
| SCHEMBL3117343 | 0.83 | PIK3CD (0.66) | PIK3CDPIK3CAMTOR | |
| SCHEMBL2919328 | 0.83 | PIK3CD (0.54) | PIK3CDPIK3CAMTOR | |
| SCHEMBL30333283 | 0.83 | PIK3CD (0.66) | PIK3CDPIK3CAMTOR | |
| SCHEMBL1621811 | 0.82 | CCR9 (0.53) | PIK3CDPIK3CAMTORAKT1 | |
| SCHEMBL1118669 | 0.81 | MCL1 (0.53) | PIK3CDPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106674200-A | Compound containing L-prolinamide fragment, and preparation method and application thereof | 西安交通大学 | 2017-05-17 | — | — | CN | claimed |
| US-12508264-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-12-30 | — | — | US | disclosed |
| US-12508263-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-12-30 | — | — | US | disclosed |
| EP-4169918-B1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF PI3K FOR THE TREATMENT OF CANCER | INST MATERIA MEDICA CAMS (CN) | 2025-07-30 | — | — | EP | disclosed |
| EP-4169917-B1 | QUINAZOLINE COMPOUNDS AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER | INST MATERIA MEDICA CAMS (CN) | 2025-07-30 | — | — | EP | disclosed |
| EP-3560921-B1 | QUINAZOLINE COMPOUND, PREPARATION METHOD, APPLICATION AS PI3K INHIBITOR FOR THE TREATMENT OF CANCER, AND PHARMACEUTICAL COMPOSTION THEREOF | INST MATERIA MEDICA CAMS (CN) | 2024-08-14 | — | — | EP | disclosed |
| EP-4169918-A1 | QUINAZOLINE COMPOUND AND PREPARATION METHOD, APPLICATION, AND PHARMACEUTICAL COMPOSTION THEREOF | Institute of Materia Medica, Chinese Academy of Medical Sciences (CN) | 2023-04-26 | — | — | EP | disclosed |
| EP-4169917-A1 | QUINAZOLINE COMPOUND AND PREPARATION METHOD, APPLICATION, AND PHARMACEUTICAL COMPOSTION THEREOF | Institute of Materia Medica, Chinese Academy of Medical Sciences (CN) | 2023-04-26 | — | — | EP | disclosed |
| US-20230113478-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMYOF MEDICAL SCIENCES (CN) | 2023-04-13 | — | — | US | disclosed |
| US-20230110550-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMYOF MEDICAL SCIENCES (CN) | 2023-04-13 | — | — | US | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009017822-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| CN-101098869-A | 5-heteroaryl thiazoles and their use as p13k inhibitors | ASTRAZENECA AB (SE) | 2008-01-02 | — | — | CN | disclosed |
| EP-1841763-A1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | AstraZeneca AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006051270-A1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS P13K INHIBITORS | ASTRAZENECA AB (SE) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054405-A1 | PI3 kinase modulators and methods of use | PIK3CA, PIK3C2A, PIK3C2B | PIK3CD 4/4885PIK3CA 1/4885MTOR 37/4885 |
| US-12508263-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | PIK3CA, PIK3R5, JAK1 | PIK3CD 5/4885PIK3CA 1/4885MTOR 15/4885 |
| US-20230113478-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | PIK3CA, PIK3CD, PDPK1 | PIK3CD 2/4885PIK3CA 1/4885MTOR 27/4885 |
| US-12508264-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | PIK3CA, PIK3C2A, PIK3R5 | PIK3CD 4/4885PIK3CA 1/4885MTOR 11/4885 |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | MTOR, PIK3R5, PIK3CA | PIK3CD 6/4885PIK3CA 3/4885MTOR 1/4885 |
| US-20090163489-A1 | Inhibitors of PI3 kinase | PIK3CA, PIK3CD, PIK3CG | PIK3CD 2/4885PIK3CA 1/4885MTOR 28/4885 |
| US-20230110550-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | PIK3CA, PIK3CD, PDPK1 | PIK3CD 2/4885PIK3CA 1/4885MTOR 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.